Antagonism of the myotoxic effects of Bothrops jararacussu venom and bothropstoxin by polyanions.
The effects of heparin and other polyanions on the myotoxicity of Bothrops jararacussu venom and purified bothropstoxin (BthTX) were investigated. The release rate of creatine kinase (CK) from isolated extensor digitorum longus muscle and the plasma CK activity of mice were used to quantify the results. The myotoxic effects of B. jararacussu venom or BthTX were inhibited by preincubation of these agents with one of the following: a heterogeneous heparin preparation (designated 'heparin'), low mol. wt heparin (H-4500) or dextran sulfates (DS-8000 and DS-500,000). Non-sulfated dextran (D-40,000) and two chondroitin sulfates were ineffective. The antimyotoxic effects of the polyanions are ascribed to their forming inactive acid-base complexes with the basic myotoxins of Bothrops venoms. Gel-filtration experiments in Sephadex provided direct evidence for complex formation between heparin and BthTX. Intravenous (i.v.) administration of H-4500 or DS-8000 opposed the increase in plasma CK activity induced by a subsequent i.m. injection of venom or BthTX. In contrast, pretreatment with i.v. heparin or DS-500,000 enhanced the venom-induced increase in plasma CK activity. This effect was not observed (1) when the animals were treated with a polyvalent antivenom, which inhibits the coagulation and local stasis induced by Bothrops venoms, and (2) when BthTX, which has no thrombotic or hemorrhagic properties, was the myotoxic agent. The potentiation of the venom-induced increase in plasma CK activity by heparin and DS-500,000 is ascribed to improved washout of the CK released from damaged fibers, because of the anticoagulant properties of the drugs.
Melo
P A
PA
Departamento de Farmacologia Básica e Clínica, Universidade Federal do Rio de Janeiro, Brazil.
Homsi-Brandeburgo
M I
MI
Giglio
J R
JR
Suarez-Kurtz
G
G
D000818:Animals; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D002850:Chromatography, Gel; D003402:Creatine Kinase / Q000378:metabolism; D003435:Crotalid Venoms / Q000037:antagonists & inhibitors* / Q000633:toxicity; D016264:Dextran Sulfate / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D049673:History, 20th Century; D051379:Mice; D008970:Molecular Weight; D009132:Muscles / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D009135:Muscular Diseases / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*
D003435:Crotalid Venoms; C078097:bothropstoxin; D006493:Heparin; D002809:Chondroitin Sulfates; D016264:Dextran Sulfate; D003402:Creatine Kinase